Recombinant Human JAK1 kinase domain His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11738-J1

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11738-J1-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P23458.2

Conjugate

Unconjugated

Applications

Bioactivity

View all Jak1 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human Jak1 protein
Met 6-His tag Sumo-tag
(mutated, uncleavable)		 3c Protease site Human JAK1
(Ala561-Lys1154)
Accession # P23458.2

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Protein identity confirmed by mass spectrometry.

Predicted Molecular Mass

81 kDa

SDS-PAGE

75-89 kDa, under reducing conditions

Activity

Measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.

The specific activity is >110 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human JAK1 kinase domain His-tag Protein, CF

Recombinant Human JAK1 kinase domain His-tag Enzyme Activity.

Recombinant Human JAK1 kinase domain His-tag (Catalog # 11738-J1) is measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.

Recombinant Human JAK1 kinase domain His-tag SDS-PAGE.

2 μg/lane of Recombinant Human JAK1 kinase domain His-tag (Catalog # 11738-J1) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-89 kDa, under reducing conditions.

Formulation, Preparation and Storage

11738-J1
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, DTT and Glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Jak1

Janus Kinase 1 (JAK1) is one of four members of the JAK, or "just another kinase", family of intracellular, non-receptor tyrosine kinases (1) that noncovalently associate with Type I and Type II cytokine receptor cytoplasmic regions to mediate receptor tyrosine and subsequent STAT protein phosphorylation. JAK1 is broadly expressed in many cell types and contains several conserved JAK homology (JH) domains that compose an N-terminal FERM domain followed by a Src homology (SH) domain that associate and mediate interaction with the cytokine receptors (2,3) and a pseudokinase domain with no catalytic activity that regulates the activity of the catalytic kinase domain present at the C-terminus (4). JAK/STAT signaling is activated by over 50 cytokines that bind to the major cytokine receptors prompting auto-activation of JAKs by transphosphorylation and subsequent phosphorylation of the receptors to promote STAT binding (1,4). Once STAT proteins are bound, JAKs phosphorylate STAT causing dissociation, dimerization, and translocation to the nucleus where they function as transcription factors and play a role in the control of hematopoiesis, the immune response, embryogenesis, inflammation, and cancer (5-8). In addition, JAK1 activating mutations have been directly reported in Castleman's disease (9) and T-cell malignancies such as activating T-ALL, Sezary Syndrome, and T-cell prolymphocytic leukemia (10-12). There is interest in development of JAK inhibitors as a therapeutic target to prevent phosphorylation of their substrates and downstream signaling pathways. Prior clinical studies targeting JAK1 have been focused on rheumatoid arthritis, myelofibrosis, and dermatology-related conditions such as psoriasis (1,13-15). 

References

  1. Agashe, R.P. et al. (2022) Mol. Cancer Ther. 21:1757. 
  2. Leonard, W.J. and J.J. O'Shea (1998) Annu. Rev. Immunol. 16:293.
  3. Wallweber, H.J. et al. (2014) Nat. Struct. Mol. Biol. 21:443.
  4. Garrido-Trigo, A. et al. (2020) J. Crohns Colitis. 14:S713. 
  5. Morris, R. et al. (2018) Protein. Sci. 27:1984. 
  6. Loh, C.Y. et al. (2019) Front. Oncol. 9:48. 
  7. Fragoulis, G.E. et al. (2019) Rheumatology 58:i43. 
  8. Brooks, A.J. and T. Putoczki. (2020) Cancers 12:1971.
  9. Patel, M. et al. (2017) JAMA Dermatol. 153:449.
  10. Kiel, M.J. et. al. (2015) Nat. Commun. 6:8470.
  11. Govaerts, I. et al. (2019) Hemasphere 3:e313.
  12. Wahnschaffe, L. et. al. (2019) Cancers 11:1833. 
  13. Harrington, R. et al. (2020) J. Inflamm. Res. 13:519. 
  14. Plosker, G.L. (2015) Drugs 75:297. 
  15. Papp, K. et al. (2021) J. Am. Acad. Dermatol. 85:863.

Long Name

Janus Kinase 1

Alternate Names

EC 2.7.10, JAK-1, JAK1Atyrosine-protein kinase JAK1, JAK1B, Janus kinase 1EC 2.7.10.2, JTK3

Entrez Gene IDs

3716 (Human)

Gene Symbol

JAK1

UniProt

P23458.2

Additional Jak1 Products

Product Documents for Recombinant Human JAK1 kinase domain His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human JAK1 kinase domain His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.